The authors demonstrated that human tumor xenografts with low murine stroma invasion show a better response to bevacizumab than those with high murine stroma invasion, as the angiogenic response predominantly relies on tumor-derived, human VEGF [30]. Here, VEGFA is linked to neoplasm.